Monitor for top-line results in late Q3 2026. Enrollment completion reduces clinical timeline risk, but no efficacy data yet. Stock may trade on trial catalysts and COVID wave dynamics over the summer.
IVVD drugs
IVVD drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 1 $1.22entry
- T+1 · 6mo ago −6.56%α −6.70% · $1.14
- T+5 · 5mo ago −15.57%α −12.82% · $1.03
- T+20 · 5mo ago −28.49%α −27.19% · $0.8724
- T+60 · 3mo ago −23.06%α −24.29% · $0.9387
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Invivyd completed enrollment in the Phase 3 DECLARATION trial evaluating VYD2311 for prevention of symptomatic COVID-19. Top-line results are expected in late Q3 2026. The trial was upsized by ~500 subjects to enhance statistical power.
Key Facts
- Enrollment completed in DECLARATION trial evaluating VYD2311 for COVID-19 prevention.
- Trial is BLA-enabling, Phase 3, randomized, placebo-controlled with ~2,400 participants.
- Sample size re-estimation added ~500 subjects to enhance statistical power.
- Top-line results expected approximately late Q3 2026.
Financial Impact
No financial data provided; successful Phase 3 data and potential BLA approval could be transformative for this pre-revenue company.
Risk Factors
- Trial failure or negative efficacy/safety data could severely impact stock.
- Regulatory hurdles for BLA submission and approval.
- Competition from vaccines and other monoclonal antibodies.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3304208 |
Track record
19 reports on IVVD
3 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +35.85% at T+20 after the Jul 6, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 16, 2026today Press Release Neutral 6/10 Entry $0.5603 Now $0.5380 −3.98% settles Nov 23
- Nov 3, 202613d ago Press Release Neutral 2/10 Entry $0.5815 to $0.5744 Now $0.5380 −7.48% ▼ −1.22% −0.63% vs SPY
- Sep 29, 20266w ago 8-K Bullish 7/10 Entry $0.8501 to $0.8064 Now $0.5380 −36.71% ▼ −5.14% −7.09% vs SPY
- Sep 22, 20267w ago Institutional Cluster Mixed 3/10 Entry $0.9640 to $0.8501 Now $0.5380 −44.19% ▼ −11.82% −10.63% vs SPY
- Sep 1, 202610w ago 8-K Neutral 6/10 Entry $0.8800 to $0.7973 Now $0.5380 −38.86% ▼ −9.40% −9.48% vs SPY
- Aug 17, 202613w ago 144 Neutral 2/10 Entry $0.8680 to $0.9387 Now $0.5380 −38.02% ▲ +8.15% +8.35% vs SPY
- Jul 6, 202619w ago 8-K Bearish 6/10 Entry $0.8340 to $0.7834 Now $0.5380 +35.49% ▲ +6.07% +6.56% vs SPY
- Jun 16, 202621w ago Press Release Neutral 5/10 Entry $0.8918 to $0.9346 Now $0.5380 −39.67% ▲ +4.80% +7.03% vs SPY
- Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $0.8125 to $0.9312 Now $0.5380 −33.78% ▲ +14.61% +14.18% vs SPY
- Jun 9, 202622w ago Press Release Neutral 4/10 Entry $0.9900 to $0.8686 Now $0.5380 −45.66% ▼ −12.26% −14.67% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers